Persistent Asset Partners Ltd Invests $670,000 in Celcuity, Inc. $CELC

Persistent Asset Partners Ltd bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 6,719 shares of the company’s stock, valued at approximately $670,000.

Several other hedge funds have also recently bought and sold shares of CELC. Squarepoint Ops LLC acquired a new position in Celcuity during the fourth quarter valued at approximately $5,690,000. Sofinnova Investments Inc. increased its position in shares of Celcuity by 18.2% in the fourth quarter. Sofinnova Investments Inc. now owns 299,417 shares of the company’s stock worth $29,864,000 after acquiring an additional 46,042 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Celcuity in the 4th quarter valued at $22,102,000. Barclays PLC raised its stake in shares of Celcuity by 137.2% in the 4th quarter. Barclays PLC now owns 122,854 shares of the company’s stock valued at $12,253,000 after acquiring an additional 71,053 shares during the period. Finally, Aigen Investment Management LP acquired a new position in shares of Celcuity during the 4th quarter valued at $355,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insider Activity

In related news, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares of the company’s stock, valued at $9,144,200. This represents a 27.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock valued at $5,111,950 over the last 90 days. Insiders own 13.33% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CELC. Citizens Jmp upped their price target on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research report on Monday, May 4th. Needham & Company LLC restated a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research note on Friday, May 15th. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Finally, Craig Hallum dropped their target price on Celcuity from $189.00 to $171.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $152.09.

Celcuity Price Performance

Shares of CELC stock opened at $87.32 on Wednesday. The firm has a fifty day simple moving average of $118.82 and a 200-day simple moving average of $111.13. The company has a market capitalization of $4.26 billion, a PE ratio of -22.39 and a beta of 0.10. Celcuity, Inc. has a twelve month low of $11.27 and a twelve month high of $151.02. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. Equities research analysts anticipate that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.